



Press release

Stockholm, 18 September 2018

Bactiguard wins another tender in Sweden

Bactiguard has won a tender for urinary catheters for the Östergötland region in Sweden, which enables healthcare providers in the region to purchase Bactiguard's urinary catheters for infection prevention in both latex and silicone. The contract is valid for at least 2 years.

"This agreement gives us the opportunity to increase our collaboration with the Östergötland region and we look forward to reducing the incidence of healthcare associated infections together", says Nina Nilsson, SVP Sales and Marketing at Bactiguard.

The contract runs from 1 October, 2018 to 30 September, 2020 and includes both BIP Foley Catheter latex and BIP Foley Catheter Silicone. In accordance with Swedish tender law, the contracting authority will execute the formal contract once the appeal period has expired on 27 September, 2018.

Bactiguard is today procured through tenders in the following Swedish regions/county councils: Stockholm, Västra Götaland, Skåne, Värmland, Kronoberg, Halland, Blekinge, Kalmar and now also Östergötland.

For more information, please contact:

Nina Nilsson, SVP Sales and Marketing, Mobile: +46 70 214 87 49

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.



Read more about how Bactiguard saves lives on www.bactiguard.com